Continuous purification of a clotting factor IX concentrate and continuous regeneration by preparative annular chromatography

被引:9
作者
Iberer, G
Schwinn, H
Josic, D
Jungbauer, A
Buchacher, A
机构
[1] Octapharma Pharmazeut Prod GesmbH, A-1100 Vienna, Austria
[2] Univ Agr Sci, Inst Appl Microbiol, A-1190 Vienna, Austria
关键词
continuous annular chromatography; preparative chromatography; factor IX; proteins; vitronectin;
D O I
10.1016/S0021-9673(02)01074-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Preparative continuous annular chromatography, a method to separate proteins in a truly continuous manner, was investigated in an industrial environment. Plasma-derived clotting factor IX concentrate was used as model protein. Separation of vitronectin, a common impurity in commercial available factor IX concentrates, from factor IX was studied and compared to conventional packed bed chromatography in batch mode. As sorbent, Toyopearl DEAF 650M was used. Regeneration was performed simultaneously with the purification of factor IX in continuous mode. All required parameters applied for preparative annular chromatography such as feed flow-rate and elution flow-rate were first estimated from experiments on conventional batch columns. Then preparative annular chromatography and conventional packed beds were compared regarding enrichment, purity and productivity. Three different process scenarios, the optimal batch process, the preparative annular chromatography process and the batch process equivalent to the preparative annular chromatography process were investigated. The productivity of the optimal batch process was higher than that of the preparative annular chromatography and batch process equivalent to the preparative annular chromatography process. Therefore the throughput could not be increased by the use of the continuous chromatographic system. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:115 / 129
页数:15
相关论文
共 48 条
[1]   ACTIVATION PEPTIDE OF HUMAN FACTOR-IX HAS OLIGOSACCHARIDES O-GLYCOSIDICALLY LINKED TO THREONINE RESIDUES AT 159 AND 169 [J].
AGARWALA, KL ;
KAWABATA, S ;
TAKAO, T ;
MURATA, H ;
SHIMONISHI, Y ;
NISHIMURA, H ;
IWANAGA, S .
BIOCHEMISTRY, 1994, 33 (17) :5167-5171
[2]   Why prescribe highly purified factor VIII and IX concentrates? [J].
Berntorp, E .
VOX SANGUINIS, 1996, 70 (02) :61-68
[3]   SEPARATION OF PROTEIN MIXTURES BY CONTINUOUS ANNULAR CHROMATOGRAPHY WITH STEP ELUTION [J].
BLOOMINGBURG, GF ;
CARTA, G .
CHEMICAL ENGINEERING JOURNAL AND THE BIOCHEMICAL ENGINEERING JOURNAL, 1994, 55 (1-2) :B19-B27
[4]   CONTINUOUS SEPARATION OF PROTEINS BY ANNULAR CHROMATOGRAPHY [J].
BLOOMINGBURG, GF ;
BAUER, JS ;
CARTA, G ;
BYERS, CH .
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 1991, 30 (05) :1061-1067
[5]  
Bond M, 1998, SEMIN HEMATOL, V35, P11
[6]   Application of monoliths for downstream processing of clotting factor IX [J].
Branovic, K ;
Buchacher, A ;
Barut, M ;
Strancar, A ;
Josic, D .
JOURNAL OF CHROMATOGRAPHY A, 2000, 903 (1-2) :21-32
[7]  
Broughton DB, 1961, U. S. Patent, Patent No. [2,985,589, 2985589]
[8]   High-performance capillary electrophoresis for in-process control in the production of antithrombin III and human clotting factor IX [J].
Buchacher, A ;
Schulz, P ;
Choromanski, J ;
Schwinn, H ;
Josic, D .
JOURNAL OF CHROMATOGRAPHY A, 1998, 802 (02) :355-366
[9]   Continuous removal of protein aggregates by annular chromatography [J].
Buchacher, A ;
Iberer, G ;
Jungbauer, A ;
Schwinn, H ;
Josic, D .
BIOTECHNOLOGY PROGRESS, 2001, 17 (01) :140-149
[10]   PROPERTIES OF A HIGHLY PURIFIED HUMAN-PLASMA FACTOR-IX-C THERAPEUTIC CONCENTRATE PREPARED BY CONVENTIONAL CHROMATOGRAPHY [J].
BURNOUF, T ;
MICHALSKI, C ;
GOUDEMAND, M ;
HUART, JJ .
VOX SANGUINIS, 1989, 57 (04) :225-232